Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

Importance Adjuvant chemotherapy in patients with stage III colon cancer prevents
recurrence by eradicating minimal residual disease. However, which patients remain at high …

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in
various body effluents such as blood or urine instead of a fragment of cancer tissue. It is …

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …

Background & Aims We aimed to investigate the clinical utility of circulating tumor cell DNA
(ctDNA) and exosome DNA (exoDNA) in pancreatic cancer. Methods We collected liquid …

Objective For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy
selection following surgery remains a major clinical dilemma. Here, we investigated the …

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is
rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma …